Clinical Trial Update: Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR) [Phase 3]

View source ↗

Summary

An open-label, long-term safety study of secukinumab in polymyalgia rheumatica is being conducted in Phase 3. The trial is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polymyalgia Rheumatica

Drugs mentioned

• Cosentyx (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Polymyalgia Rheumatica | Phase 3 | Status: ACTIVE_NOT_RECRUITING